Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
about
Metabolism-based drug interactions involving oral azole antifungals in humans.Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans.Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath testEffect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivoImpact of obesity on drug metabolism and elimination in adults and children.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2.Urinary biomarkers for assessing dietary exposure to caffeine.A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo.
P2860
Q33719828-1EA60A35-FB87-4E5B-B591-873386636187Q34297580-E12128B9-FD32-4374-9CDA-93BA89D9E3F3Q34320302-077602AF-62BB-49C0-AAAD-345B8D055B5FQ35802131-4CFDDB09-C67F-4F6C-A4A3-F6BFA6345D75Q36053651-E9BC264F-4DA8-484C-92B1-795D73315AF5Q36053773-AFEA9CAB-0F81-4BCE-8DE9-D3B18D090AF3Q37997025-C548F544-7AFA-4D46-8B3A-CCB41A008AE1Q38103885-3A435C81-A47D-411C-A7AD-20294DC9F9FEQ39952865-4EB62401-0E08-4854-B94D-AEBB4E99E80BQ43137163-16E40D6B-C3BA-4BBA-972A-25C793B7112DQ43836341-0D9CAC96-DE46-46DE-9D8B-731A9358F3A8Q46617737-F8C2567E-9CFF-4975-AEC8-43D97C156EAFQ46675103-925DD997-AFD3-4556-83E4-3AA010577E3A
P2860
Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@en
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@nl
type
label
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@en
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@nl
prefLabel
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@en
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@nl
P1476
Theophylline has no advantages ...... ing CYPIA2 activity in humans.
@en
P2093
Rasmussen BB
P304
P356
10.1111/J.1365-2125.1997.00546.X
P407
P577
1997-03-01T00:00:00Z